Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.76 |
| ▸ | CRHBP | P24387 | 1/20 | 0.73 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | XDH | P47989 | 3/20 | 0.66 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | GSK3B | P49841 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | METAP1 | P53582 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6413731 | 1.00 | IGF1R (0.76) | IGF1RCRHBPCRHR2MEN1KMT2A | |
| SCHEMBL1250596 | 0.86 | IGF1R (1.00) | IGF1RCRHBPCRHR2MEN1KMT2A | |
| SCHEMBL1250598 | 0.86 | IGF1R (1.00) | IGF1RCRHBPCRHR2MEN1KMT2A | |
| SCHEMBL13846818 | 0.86 | IGF1R (1.00) | IGF1RCRHBPCRHR2MEN1KMT2A | |
| SCHEMBL8309014 | 0.84 | CRHBP (1.00) | IGF1RCRHBPCRHR2MEN1KMT2A | |
| SCHEMBL8309015 | 0.84 | CRHBP (1.00) | IGF1RCRHBPCRHR2MEN1KMT2A | |
| SCHEMBL29441421 | 0.78 | IGF1R (0.64) | IGF1RCRHBPCRHR2MEN1KMT2A | |
| SCHEMBL8186384 | 0.78 | AKR1B1 (0.74) | MEN1KMT2AMAPTXDHGSK3B | |
| SCHEMBL8186386 | 0.78 | AKR1B1 (0.74) | MEN1KMT2AMAPTXDHGSK3B | |
| SCHEMBL6413936 | 0.77 | XDH (0.70) | IGF1RMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050019825-A9 | Common ligand mimics: pseudothiohydantoins | TRIAD THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040009527-A1 | Common ligand mimics: pseudothiohydantoins | DONG QING (US) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019825-A9 | Common ligand mimics: pseudothiohydantoins | FGFR3, BID, FLT3 | IGF1R 291/4885CRHBP 933/4885CRHR2 945/4885 |
| US-20040009527-A1 | Common ligand mimics: pseudothiohydantoins | FGFR3, BID, FLT3 | IGF1R 291/4885CRHBP 933/4885CRHR2 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.